NASDAQ:HSGX

Histogenics Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$7.56
+0.15 (+2.02 %)
(As of 06/23/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.11
$7.65
50-Day Range
$0.16
$3.07
52-Week Range
$0.08
$1.43
Volume26.81 million shs
Average Volume9.06 million shs
Market Capitalization$715.17 million
P/E RatioN/A
Dividend YieldN/A
Beta3.1

Receive HSGX News and Ratings via Email

Sign-up to receive the latest news and ratings for Histogenics and its competitors with MarketBeat's FREE daily newsletter.


Histogenics logo

About Histogenics

Histogenics Corporation develops restorative cell therapies that would offer rapid-onset pain relief and restored function. The company was founded in 2000 and is headquartered in Waltham, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.73 out of 5 stars

Medical Sector

1306th out of 2,105 stocks

Surgical Appliances & Supplies Industry

32nd out of 40 stocks

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Histogenics (NASDAQ:HSGX) Frequently Asked Questions

What stocks does MarketBeat like better than Histogenics?

Wall Street analysts have given Histogenics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Histogenics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Histogenics' earnings last quarter?

Histogenics Corp (NASDAQ:HSGX) issued its quarterly earnings data on Thursday, August, 9th. The biotechnology company reported ($0.13) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.23) by $0.10.
View Histogenics' earnings history
.

Who are Histogenics' key executives?

Histogenics' management team includes the following people:
  • Mr. Adam D. Gridley, Interim Pres, CEO Treasurer, Sec., Consultant & Director (Age 47)
  • Mr. Jonathan I. Lieber, Interim Chief Financial Officer (Age 49)
  • Mr. Stephen R. Kennedy, Consultant (Age 62)

Who are some of Histogenics' key competitors?

What other stocks do shareholders of Histogenics own?

When did Histogenics IPO?

(HSGX) raised $60 million in an IPO on Wednesday, December 3rd 2014. The company issued 4,300,000 shares at $13.00-$15.00 per share. Cowen and Company, Needham & Company and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager.

What is Histogenics' stock symbol?

Histogenics trades on the NASDAQ under the ticker symbol "HSGX."

What is Histogenics' stock price today?

One share of HSGX stock can currently be purchased for approximately $7.56.

How much money does Histogenics make?

Histogenics has a market capitalization of $715.17 million. The biotechnology company earns $-8,640,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis.

How many employees does Histogenics have?

Histogenics employs 49 workers across the globe.

What is Histogenics' official website?

The official website for Histogenics is www.histogenics.com.

Where are Histogenics' headquarters?

Histogenics is headquartered at 830 WINTER STREET 3RD FLOOR, WALTHAM MA, 02451.

How can I contact Histogenics?

Histogenics' mailing address is 830 WINTER STREET 3RD FLOOR, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-547-7900 or via email at [email protected]


This page was last updated on 6/24/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.